BERLIN (Reuters) - Swiss drugmaker Roche on Wednesday said the US Food and Drug Administration (FDA) has approved its human ...
The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday ...
The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50. GSK, the vaccine’s maker ...
FDA approves RSV vaccine The vaccine is approved for at-risk adults in their fifties, making it the first shot approved for the age group. Up Next in wellness What to know about the new vaccine for ...
Geron's CEO said the company anticipates a peak market potential of $1.2 billion in the US and some key EU countries by 2030. In March, by a 12-to-2 margin, the FDA adcomm panel voted in favor of ...
Allowing pharmacists to treat minor illnesses could potentially expand healthcare access to more people and save millions of ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA ...
mRESVIA will be available for the 2024/2025 RSV season as a pre-filled, ready to use syringe. The FDA has approved Moderna’s mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to ...
Geron (NASDAQ:GERN) shares added ~17% premarket Friday after the U.S. Food and Drug Administration (FDA) approved its lead asset, imetelstat, as a late-line option for a type of blood cancer ...